See highlights from GHTC's 2022 Innovating for Impact Awards

Search the GHTC website

Washington

Washington

Global health R&D delivers for Washington

US government investment in global health R&D has delivered

Amount
$783.9 million
to Washington research institutions
Jobs
9,700+ new jobs
for Washington
Washington

Neglected diseases in Washington

Chikungunya cases
Chikungunya cases
66
Dengue cases
Dengue cases
108
HIV diagnoses
HIV diagnoses
4338
Malaria cases
Malaria cases
211
Tuberculosis cases
Tuberculosis cases
1923
West Nile cases
West Nile cases
93
Zika cases
Zika cases
82
Washington's top USG-funded global health R&D institutions

Washington's top USG-funded global health R&D institutions

Fred Hutchinson Cancer Research Center
$449.8 million
University of Washington (including Harborview Medical Center)
$156.9 million
Center for Infectious Disease Research (formerly Seattle Biomed, Seattle Biomedical Research Institute, SBRI)
$91.5 million
PATH
$33.8 million
Infectious Disease Research Institute
$29.1 million
The Geneva Foundation
$5.1 million
Pacific Northwest National Laboratory
$4.3 million
Benaroya Research Institute at Virginia Mason
$2.8 million
Washington State University
$2.1 million
Seattle Children's Hospital (including Seattle Children's Research Institute)
$1.9 million
Global Health Cooperative (nor part of Kaiser Permanente)
$1.4 million
Gonzaga University
$505 thousand
Central Washington University
$361 thousand
Washington industry in global health R&D

Washington industry in global health R&D

Bristol-Myers Squibb
Location(s): Seattle
Celgene
Location(s): Seattle
InBios
Location(s): Seattle
Micronics
Location(s): Redmont
MSR Global Health
Location(s): Seattle
Nortis Bio
Location(s): Seattle, Woodenville

Washington's top areas of global health R&D by USG funding

66.9%
HIV/AIDS
9.5%
Malaria
8.2%
Tuberculosis
4%
Salmonella infections
6.5%
Neglected tropical diseases
Buruli ulcer
Dengue
Helminths
Kinetoplastids
Leprosy
Trachoma
5%
Other
Bacterial pneumonia & meningitis
Diarrheal diseases
Ebola/viral hemorrhagic fevers
Global health R&D at work in Washington

Several million babies born each year in Africa and Asia can’t breastfeed due to prematurity or cleft lip or palate. Tools such as breast pumps and bottles are impractical and unhygienic in settings that lack clean water and electricity. To help save these infants from starving, the University of Washington, Seattle Children’s, and PATH developed the NIFTY cup, a soft, silicone bowl with a tiny reservoir that allows these infants to lap up lifesaving breast milk.

Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: PATH/Patrick McKern